Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant	Blood Protein Disorders, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Hodgkins lymphoma, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Myeloproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, acute myeloid leukemia, bone marrow disorder, cardiovascular disorder, hematologic disorder, hematopoietic and lymphoid cell neoplasm, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, monoclonal gammopathy, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease, myelodysplastic/myeloproliferative neoplasm, myeloid leukemia, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease	Active, not recruiting	Phase 2	2026-08-06		NCT02861417

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
M.D. Anderson Cancer Center	1145
National Cancer Institute (NCI)	3015

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
M D Anderson Cancer Center	Houston	United States	667